Trial Profile
A phase II study of dasatinib (BMS-354825) in subjects with chronic or advanced phase chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) who are resistant or intolerant to imatinib
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 20 Dec 2006 Status change
- 10 Oct 2006 New trial record.